[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100566696":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":39,"centralContacts":40,"locations":46,"responsibleParty":87,"collaborators":39,"id":89,"slug":90,"hasResults":91,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":91,"sex":97,"minAge":98,"maxAge":39,"enrollmentInfo":99,"targetDuration":39,"studyType":102,"phases":103,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":49,"whyStopped":39,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},{"fullName":5,"class":6},"NuvOx LLC","INDUSTRY",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 0.025","EXPERIMENTAL","Loading dose = 0.025 mL\u002Fkg followed sustained IV infusion of 0.375 mL\u002Fkg over 21 hours.",[13],"Drug: dodecafluoropentane (0.025 mL\u002Fkg)",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort 0.032","Loading dose of 0.032 mL\u002Fkg followed sustained IV infusion of 0.48 mL\u002Fkg over 21 hours.",[18],"Drug: dodecafluoropentane (0.032 mL\u002Fkg)",{"label":20,"type":10,"description":21,"interventionNames":22},"Cohort 0.050","Loading dose of 0.050 mL\u002Fkg followed by sustained IV infusion of 0.75 mL\u002Fkg over 21 hours.",[23],"Drug: dodecafluoropentane (0.050 mL\u002Fkg)",[25,31,35],{"type":26,"name":27,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","dodecafluoropentane (0.025 mL\u002Fkg)",[9],[30],"NanO2™",{"type":26,"name":32,"description":32,"armGroupLabels":33,"otherNames":34},"dodecafluoropentane (0.032 mL\u002Fkg)",[15],[30],{"type":26,"name":36,"description":36,"armGroupLabels":37,"otherNames":38},"dodecafluoropentane (0.050 mL\u002Fkg)",[20],[30],null,[41],{"name":42,"role":43,"phone":44,"phoneExt":39,"email":45},"NuvOx Pharma","CONTACT","520-624-6688","EXTEND_Clinical@nuvoxpharma.com",[47,69],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Grey Nun Community Hospital","RECRUITING","Edmonton","Alberta","T6L 5X8","Canada","CA",{"type":56,"coordinates":57},"Point",[58,59],-113.46871,53.55014,{"lat":59,"lon":58},[62,66],{"name":63,"role":43,"phone":64,"phoneExt":39,"email":65},"Anushka Jayasekara","587-590-5295","Anushka.Jayasekara@covenanthealth.ca",{"name":67,"role":68,"phone":39,"phoneExt":39,"email":39},"Janek Senaratne, MD","PRINCIPAL_INVESTIGATOR",{"facility":70,"status":49,"city":71,"state":72,"zip":73,"country":53,"countryCode":54,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"Hôpital Maisonneuve Rosemont","Montreal","Quebec","H1T 2M4",{"type":56,"coordinates":75},[76,77],-73.58781,45.50884,{"lat":77,"lon":76},[80,85],{"name":81,"role":43,"phone":82,"phoneExt":83,"email":84},"Danaë Tassy, PhD","514-252-3400","4679","danae.tassy.cemtl@ssss.gouv.qc.ca",{"name":86,"role":68,"phone":39,"phoneExt":39,"email":39},"François Marquis, MD",{"type":88,"investigatorFullName":39,"investigatorTitle":39,"investigatorAffiliation":39,"oldNameTitle":39,"oldOrganization":39},"SPONSOR","100566696","phase-1-a-dose-escalation-study-of-nano2-in-patients-with-mild-respiratory-distress-100566696",false,"NCT06658535","A Dose Escalation Study of NanO2 in Patients With Mild Respiratory Distress","Novel Oxygen Therapeutic NanO2 for Mild Respiratory Distress in Phase 1b","EXTEND-1b","Inclusion Criteria:\n\n* Requiring supplemental oxygen but ≤ 6L oxygen by nasal cannula to maintain an oxygen saturation \\>92% or PaO2 \\>60mmHg\n* Admitted to a hospital with symptoms of mild RD\n* Signed informed consent obtained from the subject or subject's legally authorized representative\n* Agrees to not participate in another clinical trial for the treatment of mild RD through Day 28\n\nExclusion Criteria:\n\n* Presence of extracorporeal membrane oxygenation\n* Unstable hypertension\n* History of significantly impaired renal function defined as an eGFR ≤ 30mL\u002Fmin\u002F1.73m2 (MDRD equation or similar) or impaired hepatic function defined as the presence of decompensated cirrhosis (acute deterioration in liver function characterized by jaundice, ascites, hepatic encephalopathy, hepatorenal syndrome, or variceal hemorrhage)\n* Presence of pulmonary embolism at baseline\n* Evidence of right ventricular heart failure\n* Unstable hemodynamically as defined by receiving 0.5μg\u002Fkg\u002Fmin or greater norepinephrine\n* Inability to comply with the study procedures\n* Currently pregnant or breastfeeding\n* Anticipated discharge from the hospital or transfer to another hospital which is not a study site within 48 hours\n* History or evidence of any other clinically significant condition that, in the opinion of the investigator, might pose a safety risk to subjects or interfere with study procedures, evaluation, or completion","ALL","18 Years",{"count":100,"type":101},18,"ESTIMATED","INTERVENTIONAL",[104],"PHASE1","EXTEND is a dose escalation study of NanO2™ in patients with mild respiratory distress who are at risk for mechanical ventilation. The study will establish dosing guidelines for a Phase 2 study.",[107],"Mild Respiratory Distress",[109],"respiratory distress","2026-01-27",{"date":112,"type":113},"2026-01-28","ACTUAL",{"date":115,"type":113},"2025-03-13",{"date":117,"type":101},"2026-12",{"name":5,"class":6},2]